Commerce Bank Acquires Shares of 11,445 AtriCure, Inc. $ATRC

Commerce Bank bought a new position in AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,445 shares of the medical device company’s stock, valued at approximately $320,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the second quarter valued at approximately $37,000. Smartleaf Asset Management LLC boosted its position in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in AtriCure in the 2nd quarter valued at $40,000. Allworth Financial LP bought a new position in AtriCure in the 2nd quarter valued at $43,000. Finally, Fifth Third Bancorp purchased a new stake in shares of AtriCure during the 1st quarter valued at $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Stock Down 1.5%

ATRC stock opened at $48.54 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 231.15 and a beta of 1.20. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.98. The stock has a fifty day moving average of $37.89 and a 200-day moving average of $32.26.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at AtriCure

In related news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director directly owned 14,015 shares in the company, valued at approximately $538,456.30. The trade was a 19.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares in the company, valued at $3,888,497.20. The trade was a 5.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 53,616 shares of company stock worth $2,149,994 in the last ninety days. Insiders own 4.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ATRC. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Canaccord Genuity Group increased their price target on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research raised their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and an average target price of $49.89.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.